ITD-1

Catalog No.S6713 Batch:S671302

Print

Technical Data

Formula

C27H29NO3
Molecular Weight 415.52 CAS No. 1099644-42-4
Solubility (25°C)* In vitro DMSO 83 mg/mL (199.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ITD-1 is a potent TGF-β inhibitor. It does not block the kinase activity of either type I (TGFBR1) or type II (TGFBR2) TGFβ receptors but potently blocks phosphorylation of the effector SMAD2/3 proteins induced by TGFβ2, and only minimally in response to Activin A.
Targets
TGF-β [1]
In vitro

ITD-1, a small molecule inhibitor of TGF-β signaling, can partially induce proteasomal degradation of the TβR232,33, and blocks Smad and MAPK activation.[2]
In vivo

ITD-1 partially inhibits TGF-β signaling and renal fibrosis in unilateral ischemia-reperfusion injury (UIRI) mice.[2]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    NRK-49F cells

  • Concentrations

    3 μM

  • Incubation Time

    1 h

  • Method

    NRK-49F cells are pre-incubated with KP1 (10 µg/ml, 3 μM) or ITD-1 (3 μM) for 1 h, and then treated with TGF-β1 (2 ng/ml) for 45 min. Western blot analyses the protein levels of p-Smad3 and p-p38.

Selleck's ITD-1 has been cited by 12 publications

Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer [ Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00989-9] PubMed: 39283477
Alpha-hederin reprograms multi-miRNAs activity and overcome small extracellular vesicles-mediated paclitaxel resistance in NSCLC [ Front Pharmacol, 2024, 15:1257941] PubMed: 38362150
Adipose stem cells-derived small extracellular vesicles transport Thrombospondin 1 cargo to promote insulin resistance in gestational diabetes mellitus [ Diabetol Metab Syndr, 2024, 16(1):105] PubMed: 38764083
KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway [ Cell Mol Biol Lett, 2023, 28(1):32] PubMed: 37076815
Tripartite motif-containing 9 promoted proliferation and migration of bladder cancer cells through CEACAM6-Smad2/3 axis [ J Cell Commun Signal, 2023, 10.1007/s12079-023-00766-7] PubMed: 37249822
A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling [ Nat Commun, 2022, 13(1):438] PubMed: 35064106
TGF-β induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-α/NF-κB signal pathway [ Cell Death Dis, 2022, 13(4):339] PubMed: 35418179
HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis [ J Exp Clin Cancer Res, 2021, 40(1):62] PubMed: 33563300
Discovery of a novel short peptide with efficacy in accelerating the healing of skin wounds [ Pharmacol Res, 2020, S1043-6618(20)31604-2] PubMed: 33220421
Human induced pluripotent stem cell-derived cardiomyocytes reveal abnormal TGFβ signaling in type 2 diabetes mellitus. [ J Mol Cell Cardiol, 2020, 3;142:53-64] PubMed: 32251671

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.